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ardiac Resynchronization Therapy Improves
eart Rate Profile and Heart Rate Variability
f Patients With Moderate to Severe Heart Failure
ecilia Fantoni, MD,*† Santi Raffa, MD,* Francois Regoli, MD,* Francesco Giraldi, MD,‡
aria Teresa La Rovere, MD,§ John Prentice, PHD, Francesca Pastori, MD,* Simona Fratini, MD, PHD,*
orge A. Salerno-Uriarte, MD,† Helmut U. Klein, MD,* Angelo Auricchio, MD, PHD*
agdeburg, Germany; Varese, Milan, and Pavia, Italy; and Boulder, Colorado
OBJECTIVES This study sought to report long-term changes of cardiac autonomic control by continuous,
device-based monitoring of the standard deviation of the averages of intrinsic intervals in the
288 five-min segments of a day (SDANN) and of heart rate (HR) profile in heart failure (HF)
patients treated with cardiac resynchronization therapy (CRT).
BACKGROUND Data on long-term changes of time-domain parameters of heart rate variability (HRV) and
of HR in highly symptomatic HF patients treated with CRT are lacking.
METHODS Stored data were retrieved for 113 HF patients (New York Heart Association functional class
III to IV, left ventricular ejection fraction 35%, QRS 120 ms) receiving a CRT device
capable of continuous assessment of HRV and HR profile.
RESULTS The CRT induced a reduction of minimumHR (from 63 9 beats/min to 58 7 beats/min,
p  0.001) and mean HR (from 76  10 beats/min to 72  8 beats/min, p  0.01) and an
increase of SDANN (from 69 23 ms to 93 27 ms, p 0.001) at three-month follow-up,
which were consistent with improvement of functional capacity and structural changes.
Different kinetics were observed among these parameters. The SDANN reached the plateau
before minimum HR, and mean HR was the slowest parameter to change. Suboptimal left
ventricular lead position was associated with no significant functional and structural
improvement as well as no change or even worsening of HRV. The two-year event-free
survival rate was significantly lower (62% vs. 94%, p  0.005) in patients without any
SDANN change ( change 0%) compared with patients who showed an increase in
SDANN ( change 0%) four weeks after CRT initiation.
CONCLUSIONS Cardiac resynchronization therapy is able to significantly modify the sympathetic-
parasympathetic interaction to the heart, as defined by HR profile and HRV. Lack of HRV
improvement four weeks after CRT identifies patients at higher risk for major cardiovascular
events. (J Am Coll Cardiol 2005;46:1875–82) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.081Cardiology Foundation
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miminished heart rate variability (HRV) and increased
ean heart rate (HR) in patients with heart failure (HF) are
ssociated with a poor prognosis (1–3). There is initial
vidence that cardiac resynchronization therapy (CRT)
ncreases time-domain parameters of HRV and reduces
ean HR (4–7). Similar to other interventions and drugs
hat improve the time-domain parameters of HRV and
educe mean HR resulting in an improved prognosis (8,9),
RT also improves short-term prognosis and reduces hos-
italization rate (10,11) and mortality (12). However, data
n long-term changes of time-domain parameters of HRV
nd HR of highly symptomatic HF patients treated with
RT devices are lacking.
From the *Division of Cardiology, University Hospital, Magdeburg, Germany;
Department of Cardiovascular Sciences, University of Insubria, Varese, Italy;
Centro Cardiologico Monzino, Milan, Italy; §Department of Cardiology, Centro
edico di Montescano, S. Maugeri Foundation, IRCSS, Pavia, Italy; and Wild Rose
iophysics, Boulder, Colorado.D
Manuscript received March 1, 2005; revised manuscript received May 8, 2005,
ccepted June 6, 2005.Time-domain parameters of HRV in CRT patients have
o far been recorded by using either conventional ambula-
ory Holter monitoring (4,6), by analyzing the HR histo-
ram of sensed atrial events recorded in the CRT systems
5), or by calculating the standard deviation of a five-min
edian atrial-atrial sensed interval (7). Conventional HRV
ecording may have limited applicability for repeated mea-
urements in daily practice. On the other hand, the standard
eviation of the atrial cycle length using 10 beats/min
evice-based histogram resolution as calculated by Adam-
on et al. (5) may be not sensitive enough in recording small
ut meaningful changes of mean HR and time-domain
arameters of HRV. Furthermore, this requires manual
ownloading and off-line data analysis.
The increased storage capability of the CRT devices and
igh reliability of their algorithms allow beat-to-beat anal-
sis that enables continuous sampling of the minimum,
aximum, and mean HR as well as repeated 24-h auto-
atic calculation of the HRV time-domain parameters.
evice-based automatic monitoring of HR and time-
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CRT and Heart Rate Variability November 15, 2005:1875–82omain parameters of HRV has been recently reported (7);
his approach may be particularly helpful in evaluating
ong-term dynamic changes of both HR and HRV after
RT in HF patients.
We aimed to report long-term changes of cardiac auto-
omic control assessed by continuous, device-based moni-
oring of both HRV and HR profile in advanced HF
atients with implanted CRT devices. Furthermore, we
ssessed whether different changes in HRV time-domain
arameters after CRT could be associated with different
rognoses.
ETHODS
atients. The device-stored HR and HRV data were
etrieved for 113 consecutive patients with New York Heart
ssociation functional class III or IV, despite stable (3
onths) optimized medical therapy, left ventricular systolic
ysfunction (ejection fraction35%, end-diastolic diameter
55 mm), and ventricular conduction disturbances (QRS
uration 120 ms). All patients had been hospitalized at
east once in the previous year because of HF. All patients
ave been referred to the Division of Cardiology, University
ospital in Magdeburg for non-pharmacological treatment
f HF and received a CRT device capable of continuous
ssessment of HRV and HR profile (Renewal I, II, and IV
s well as Contak TR2, Guidant, St. Paul, Minnesota). The
esearch protocol was approved by the locally appointed
thical committee, and all patients provided oral and written
nformed consent to device implantation and agreed to data
etrieval and analysis.
Patients with permanent atrial fibrillation were excluded
ecause of the inability of the device to calculate HR and
RV. Etiology was documented by coronary angiography
n all patients before implantation. Mechanical asynchrony
s assessed by tissue Doppler imaging was not routinely
valuated and did not constitute an inclusion criterion.
CRT was delivered by a left ventricular lead implanted
nto a tributary vein of the coronary sinus in addition to a
tandard right ventricular lead and a right atrial lead. The
eft ventricular lead position was reviewed by two indepen-
ent investigators. The atrioventricular delay was optimized
Abbreviations and Acronyms
CRT  cardiac resynchronization therapy
CRT-D  cardiac resynchronization therapy device with
defibrillator back-up
HF  heart failure
HR  heart rate
HRV  heart rate variability
SDANN  standard deviation of the averages of
intrinsic intervals in the 288 five-min
segments of a day
SDNN  standard deviation of RR intervalsy invasive monitoring of pulse pressure or left ventricular (P/dt as reported by Auricchio et al. (13). All CRT devices
ere programmed in atrial-synchronous biventricular pac-
ng with the lower rate limit set at 40 beats/min, and the
pper rate limit was set at 130 beats/min.
After implantation, the first follow-up was performed at
ne month, then at the third and sixth month and then
very six months. At each follow-up, stored data including
rrhythmic episodes were retrieved and saved onto disks for
urther off-line analysis. Echocardiographic evaluation and
ymptom-limited cardiopulmonary exercise testing were
erformed before, 6 months after, and 12 months after
RT implantation.
Major cardiac events were considered as death for any
ause, implantation of a left ventricular assist device or
rgent heart transplantation, hospitalization for cardiovas-
ular reasons, and DC shock by device for ventricular
rrhythmias.
R profile and HRV evaluation. The Contak Renewal
evices enable automatic continuous recording of the fol-
owing parameters: minimum HR, mean HR, maximum
R, and standard deviation of the averages of intrinsic
ntervals in the 288 five-min segments of a day (SDANN).
or each parameter the weekly averages are provided. Paced
trial beats, supraventricular and ventricular premature
eats, and arrhythmic episodes are excluded from the
nalysis by the device. Furthermore, the devices provide the
ercentage of time during the 24-h collection period in
hich there were valid intrinsic atrial beats. If this percent-
ge falls below 67%, data will not be displayed for that
ollection period. Baseline value of mean HR, minimum
R, maximum HR, and SDANN are considered the
verage of the first week after CRT implantation.
tatistics. All data are expressed as mean  standard
eviation. An exponential fitting equation (Appendix) was
sed to describe the dynamic changes of HR and SDANN.
he values at 90%, 95%, and 99% of the plateau are
eported. Comparisons between baseline and plateau values
f each considered parameter were made using a paired
tudent t test. Comparisons between groups were per-
ormed using an unpaired Student t test and a chi-square
est. The difference in cardiac event rate over time was
nalyzed by Kaplan-Meier and log-rank tests; SPSS soft-
are version 10 (SPSS Inc., Chicago, Illinois) was used,
nd for all tests the level of significance was set at a value
f 0.05.
ESULTS
able 1 summarizes the clinical and demographic char-
cteristics of the whole population. Most of the patients
ere men presenting with coronary artery disease, de-
ressed left ventricular ejection fraction, and severely
ilated ventricles, in advanced functional class despite
est optimized medical therapy. About 37% of patients
uffered from diabetes. The vast majority of patients
82%) received a CRT device with a cardioverter-
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November 15, 2005:1875–82 CRT and Heart Rate Variabilityefibrillator back-up (CRT-D), which was indicated
ecause of a history of ventricular arrhythmias (29%) or
or primary prevention of sudden cardiac death (71%).
bout 16% of patients received amiodarone for atrial
brillation prevention or suppression of runs of ventric-
lar tachycardia. The vast majority of patients (82%)
nderwent de novo implantation, and 20 patients re-
eived a device replacement 43  18 months after the
rst CRT implantation.
Clinical follow-up and device interrogation were possible
n all patients. Frequent paroxysmal episodes of atrial
brillation were recorded in 13 patients, and marked sinus
radycardia requiring continuous atrial-based pacing oc-
urred in 6 patients. Both conditions prevented automatic
alculation of time-domain parameter of HRV and record-
ng of HR profile. The demographic, echocardiographic,
nd hemodynamic parameters of these patients did not
iffer in any way from those of the 94 patients (83%) who
aintained stable sinus rhythm for at least one year after
mplantation.
Except for diuretics, which were frequently reduced, no
urther dosage adjustment of angiotensin-converting en-
yme inhibitors or angiotensin-receptor blockers was usually
able 1. Clinical Characteristics of the Study Population
umber of patients 113
ale (%) 78
ge (yrs) 62  9
AD (%) 60
iabetes (%) 37
YHA functional class III/IV 106/7
jection fraction (%) 21  6
VEDD (mm) 69  9
eak VO2 (ml/kg/min) 14.3  3.5
RS duration (ms) 159  27
ean PCWP (mm Hg) 15  10
CE-I/ARB (%) 98
eta-blockers (%) 96
ldosterone antagonists (%) 34
iuretics (%) 100
igitalis (%) 50
miodarone (%) 16
RT-D (%) 82
CE-I  angiotensin-converting enzyme inhibitors; ARB  AT1 receptor blockers;
AD coronary artery disease; CRT-D cardiac resynchronization therapy device with
efibrillator back-up; LVEDD left ventricular end-diastolic diameter; NYHANew
ork Heart Association; peak VO2  oxygen consumption at peak exercise; PCWP 
ulmonary capillary wedge pressure.
Table 2. Changes of HR Profile and of SDAN
CRT Device and in Those With a Device Rep
De Novo
Baseline 2 Week
Minimum HR (beats/min) 63  9 61  10
Mean HR (beats/min) 76  10 74  11
Maximum HR (beats/min) 95  10 97  13
SDANN (ms) 69  23 84  29
*Significantly different (p  0.005) compared with previous
implantation.CRT  cardiac resynchronization therapy; HR  heart rate;
intervals in the 288 five-minute segments of a day.ade. No patient was crossed over to any other beta-
locking agent, but dosage increase was attempted in six
atients four to six months after implantation.
R profile and HRV after CRT implantation. A signif-
cant reduction of minimum HR (from 63 9 beats/min to
8 7 beats/min, p 0.001) and mean HR (from 76 10
eats/min to 72  8 beats/min, p  0.01) occurred. This
as concurrent with a significant increase of SDANN (from
9  23 ms to 93  27 ms, p  0.001) and maximum HR
from 95  10 beats/min to 98  11 beats/min, p  0.01)
hree months after starting CRT in patients with de novo
mplantation (Table 2). The magnitude of the changes from
aseline to three months was similar in both patients with
oronary artery disease and idiopathic dilated cardiomyop-
thy as well as in both diabetic and non-diabetic patients.
Characteristic dynamic changes of SDANN, mean HR,
inimum HR, and maximum HR were observed. Apart
rom maximum HR, in all cases of new device implantation
here was a monotonic exponential distribution of the data
oints (Appendix). The exponential curves that best fit the
verall data as well as the mean based on raw data at one
eek and at 90%, 95%, and 99% of the plateau in patients
ith new device implantation are presented in Figure 1. In
hese patients, most of the changes occurred within 12
eeks after device implantation. However, different kinetics
ere observed among parameters. The SDANN reached
he 90%, 95%, and 99% of the plateau value before mini-
um HR. Mean HR was the latest parameter to change
Fig. 1).
ew implantation versus device replacement. Patients
ith de novo implantation differed from the others (Table
) because they had a more prevalent ischemic etiology (p
.01) and more frequently received a CRT-D device (p 
.01). All other clinical, echocardiographic, and hemody-
amic parameters were not significantly different between
he two groups.
In patients in whom a CRT device was replaced with a
ew one capable of automatic monitoring of HRV,
DANN showed higher first-week and second-week values
ompared with patients with de novo implantation (Table
). Subsequently, patients with a device replacement showed
small but insignificant change of mean HR and SDANN
hree months after replacement. The values of mean HR
Patients With De Novo Implantation of a
ent
Replacement CRT
3 Months Baseline 2 Weeks 3 Months
58  7* 61  8 60  6 61  3
72  8* 75  10 76  7 74  6
98  11 94  14 98  13 103  7
93  27* 87  27 91  12 100  22
-up. Baseline values refers to averages of the first week afterN in
lacem
CRT
s
*
*
*
followSDANN  standard deviation of the averages of intrinsic
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CRT and Heart Rate Variability November 15, 2005:1875–82nd SDANN reached two weeks after replacement were not
ignificantly different from those recorded three months
fter implantation in patients who received a new device
Table 2).
RV changes after CRT and outcome. Among patients
ho maintained stable sinus rhythm and received a de novo
RT device (74 patients), nine patients (12%) experienced
major cardiac event over two years of follow-up. Two
igure 1. Dynamic changes of standard deviation of the averages of
ntrinsic intervals in the 288 five-min segments of a day (SDANN), mean
eart rate (HR), and minimumHR based on fitted data (filled circles). For
aseline, 90%, 95%, and 99% of the value to plateau, the mean value based
n the raw data (open circles) is reported with the standard error (Y axis).
able 3. Clinical Characteristics of Patients With De Novo
mplantation of a CRT Device and of Those With
Device Replacement
De Novo
CRT
Replacement
CRT p Value
umber of patients 93 20
ale (%) 80 70 NS
ge (yrs) 63  9 61  7 NS
AD (%) 67 30 0.01
iabetes (%) 36 47 NS
YHA functional class
III/IV
86/7 20/0 NS
jection fraction (%) 20  6 22  5 NS
VEDD (mm) 68  8 70  10 NS
eak VO2 (ml/kg/min) 13.4  2.9 15.3  2.3 NS
RS duration (ms) 155  25 166  28 NS
ean PCWP (mm Hg) 15  10 14  10 NS
CE-I/ARB (%) 98 100 NS
eta-blockers (%) 96 95 NS
ldosterone antagonist (%) 37 20 NS
iuretics (%) 100 100 NS
igitalis (%) 46 65 NS
miodarone (%) 17 10 NS
RT-D (%) 88 60 0.01cbbreviations as in Table 1.atients died (one because of HF and one due to myocardial
nfarction), one underwent urgent cardiac transplantation,
hree were hospitalized because of HF, and three received
n appropriate shock from the implantable cardioverter
efibrillator device. The two-year event-free survival rate
as significantly different (p  0.005) based on the change
f SDANN four weeks after implantation (Fig. 2). Patients
n whom SDANN failed to increase or even worsened (first
ertile of SDANN delta change, 0%) had the lowest
wo-year event-free survival rate (62%). Indeed, nearly all
ardiac events (seven of nine) occurred in these patients; the
ean time to first event was 87  34 days. By contrast,
atients in whom minor (second tertile, SDANN delta
hange ranging from 0% to 17%) or large (third tertile,
DANN delta change 17%) changes of SDANN were
ecorded had two-year event-free survival rates as high as
4% (Fig. 2). The difference also remained statistically
ignificant among strata (p  0.01) when DC shocks were
xcluded (Fig. 2).
Based on changes of HRV after CRT, non-responders to
RT were defined as patients (n  26) in whom SDANN
ailed to improve or even worsened (SDANN delta change
0%) four weeks after implantation. Responders to CRT
ere considered to be those patients (n  48) who showed
n increase of SDANN (SDANN delta change 0%) four
eeks after starting CRT.
At baseline, responders and non-responders to CRT did
ot significantly differ in any clinical, echocardiographic, or
emodynamic parameter. Nevertheless, the left ventricular
ead tip position significantly differed (Fig. 3), being more
requently placed in a lateral or posterolateral region in
esponders compared with non-responders (90% vs. 63%,
 0.02). At one-year follow-up, only responders showed
statistically significant improvement of peak VO2 con-
umption, left ventricular ejection fraction, and left ventric-
lar end-diastolic diameter (Fig. 3).
ISCUSSION
he results of this study show that in symptomatic HF
atients, CRT determines long-term sustained changes of
RV and HR profile that are consistent with improvement
f functional capacity and structural changes. The changes
f these parameters usually peaked within a few months
fter implantation of a new CRT device, and remained
table years thereafter. The dynamic changes of SDANN,
ean HR, and minimum HR were similar, but they peaked
t different times after starting CRT, with SDANN being
he earliest parameter to change. Lack of increase in
DANN four weeks after CRT implantation identified
atients at highest risk for major cardiovascular events such
s death, urgent heart transplantation, DC shock for fast
entricular tachyarrhythmias, and hospitalization for cardio-
ascular reasons. Moreover, these patients showed no sig-
ificant improvement of exercise capacity and no significant
hange in left ventricular ejection fraction and end-diastolic
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November 15, 2005:1875–82 CRT and Heart Rate Variabilityigure 2. The two-year cumulative event-free survival rate in patients with no changes in standard deviation of the averages of intrinsic intervals in the 288
ve-minute segments of a day (SDANN) four weeks after implantation (first tertile,  change 0%), in patients with some SDANN changes (second
ertile,  change from 0 to 17%), and in those with large SDANN changes (third tertile,  change 17%). CRT  cardiac resynchronization therapy; CV
ospitalization  hospitalizations for cardiovascular reasons.igure 3. Change of left ventricular ejection fraction, left ventricular end-diastolic diameter, and oxygen consumption at peak exercise from baseline to
ne-year follow-up (FU) in responders (dotted lines) and non-responders (continuous lines) to cardiac resynchronization therapy (CRT), according to
hanges of standard deviation of the averages of intrinsic intervals in the 288 five-minute segments of a day (SDANN) four weeks after CRT implantation.
he vertical bars represent the standard error. The p values refer to comparison between baseline and follow-up among each group. (Bottom right)
istribution of locations of the left ventricular lead tip in a left anterior oblique (LAO) 40° view among responders and non-responders. The p value refers
o comparison between responders and non-responders.
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CRT and Heart Rate Variability November 15, 2005:1875–82iameter, which was most likely due to suboptimal left
entricular lead implantation.
utomatic monitoring of HR profile and HRV. Device-
ased continuous monitoring of autonomic tone balance is
n appealing technological advance with large therapeutic
nd possibly prognostic implications. Adamson et al. (7)
ave recently reported that full automatic device-based
onitoring of time domain parameters of HRV is feasible.
ur data recorded over a longer follow-up time confirm the
bservations of Adamson et al. (7). Although the device
utomatically evaluates parameters such as mean HR, HR
ange, and SDANN, at the present time manual download-
ng at each follow-up visit is still required. Device evolution
nd improved internet-based database capability may enable
utomatic downloading, thus providing daily access to
atient’s stored data.
Automatic monitoring of either HR profile or HRV
ime-domain parameters may help in forecasting major
ardiovascular events in CRT patients. Our data indicate
hat each monitored parameter stabilizes at several weeks
fter initiation of CRT, with SDANN being the first
arameter to both change and reach a plateau. Thus, timely
ecognition of drift from its initial value may be used for
arning (7).
ffect of CRT on HR profile and HRV. This study
hows that HF patients with ventricular conduction distur-
ances who remain symptomatic despite tailored medical
herapy, have low SDANN values, and have high mean HR
t baseline. In these patients, CRT showed a favorable effect
n sympathovagal balance with a withdrawal of sympathetic
ominance as shown by the increase of SDANN and the
eduction of mean HR. The changes in HR and HRV
ecorded in our patients were similar to those observed by
lonso et al. (4), Adamson et al. (5,7), and Livanis et al. (6)
t similar follow-up periods. These changes were parallel
o improvements of functional capacity and ventricular
unction.
Our findings expand previous knowledge showing a
ime-dependent effect of CRT on SDANN and HR profile
ith the data showing an exponential curve. The increase of
RV and the reduction of mean HR were mostly observed
fter three to four months of CRT and then remained stable
or years. Indeed, the second week values of SDANN, mean
R, and minimum HR of patients in whom a CRT device
as replaced (usually three to four years after first implan-
ation) were very similar to those of de novo patients
ecorded at three months of follow-up.
Values of SDANN below 120 ms are abnormal, and
hose in the range of 50 to 70 ms in a patient cohort similar
o our study population have been reported to be associated
ith poor prognosis (2). By contrast, patients with SDANN
alues above this cut-off have a better outcome (2). In the
ajority of our patients we observed an increase of SDANN
anging in values from 60 to 70 ms at baseline to 90 to 100
s or more after CRT. This may suggest a reduced
robability of cardiovascular events. Indeed, in those pa- vients in whom SDANN increased, rare cardiovascular
vents or implantable cardioverter defibrillator shocks oc-
urred over the follow-up period. In contrast, in about 30%
f our patients, SDANN either did not change or reduced
ven further after CRT, which resulted in a 38% two-year
umulative event rate incidence. Adamson et al. (7) used the
verage HRV value measured between five to eight weeks
fter implantation for risk stratification showing that a low
DANN value was associated with increased mortality risk.
n contrast, we considered the prognostic value of HRV
hanges induced by CRT. Furthermore, compared with the
nalysis of Adamson et al. (7), who excluded the first four
eeks after CRT implantation, this study has shown that
his period of time is particularly useful for recognizing
atients at high risk of further events. This observation
eeds to be further evaluated in a larger prospective con-
rolled study.
Our patient cohort was similar to the patients included in
he Comparison of Medical Therapy, Pacing, and Defibril-
ation in Heart Failure (COMPANION) trial (11). In this
tudy the survival curves of CRT and CRT-D patients
howed a different behavior; the two survival curves sepa-
ated early on and thereafter remained parallel (11). Intrigu-
ngly, readjustment of the sympathovagal balance with a
ithdrawal of sympathetic dominance was particularly pro-
ounced during the first three months in our patients and
as completed about six months after device implantation
99% of the SDANN plateau). This may suggest a lower
ikelihood of developing ventricular tachyarrhythmias after a
ertain period of CRT, as reported by Higgins et al. (14).
nderlying pathophysiological mechanisms. The CRT-
nduced hemodynamic changes are usually considered to be
he unique mechanism responsible for the positive effect of
he therapy. Indeed, most studies have so far emphasized
he importance of improved coordination of the septal and
ateral wall contraction (13), reduction of mitral regurgita-
ion, and improvement of ventricular filling (15,16). Our
ata possibly suggest a further mechanism that may improve
ardiac efficiency, i.e., slowing of the HR. This may have a
eneficial effect on diastolic times and on myocardial oxygen
emand. Interestingly, the absolute and relative magnitude
f the change of HR during CRT is similar to that observed
uring beta-blocker treatment for patient populations pre-
enting similar clinical characteristics (17,18).
We observed that SDANN changes preceded HR
hanges after CRT. There are at least two possible expla-
ations for the improvement in HRV after CRT. Sensory
nput from cardiac receptors to the central nervous system is
rofoundly altered in patients with cardiac disease by a
ariety of mechanisms including ischemia, as well as me-
hanical distortion of afferent fibers in the presence of
bnormalities in regional contraction and in the geometry of
he beating heart (19). Deranged inputs from cardiac
eceptors might be restored by CRT with an ensuing
eduction in sympatho-excitation. This would restore tonic
agal efferent activity to the sinus node. The effects of
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November 15, 2005:1875–82 CRT and Heart Rate Variabilitynloading ventricular cardio-inhibitory receptors (20) or
mproved ventricular filling capacity might also play a role.
n particular, partial or complete removal of such a reflex
ay become evident once reverse ventricular remodeling has
ully taken place, usually at around three to six months after
tarting CRT (21). Furthermore, altered ventricular con-
raction patterns depending on both the underlying cardio-
yopathy and the conduction defects lead to an altered
rterial pressure profile that affects autonomic modulation
ia the arterial baroreceptors. Changes in dP/dt may posi-
ively affect baroreflex modulation of autonomic activity
esulting in a decrease in sympathetic and an increase in
agal efferent activity at the sinus node. Direct recordings of
ympathetic neural activity in patients with reduced left
entricular systolic function were obtained by Hamdan et al.
22), who showed a significant reduction of neural activity
fter left ventricular and biventricular pacing.
These pathophysiological hypotheses are strengthened by
he evidence that in those patients in whom unchanged
odulation or worsening of autonomic nervous system
alance occurred during CRT, left ventricular lead position
as suboptimal. This has possibly resulted in a suboptimal
elivery of CRT leading to no improvement in oxygen
onsumption at peak exercise, no major structural changes,
nd poor outcome.
All together, the data of this study suggest that CRT can
ct through several cardiac and systemic mechanisms to
odulate the autonomic nerve system. These data are
onsistent with recent findings showing reduction of the
ystemic level of norepinephrine and brain natriuretic pep-
ide after CRT (23,24). However, further prospective stud-
es with serial assessment of autonomic tone including
eurohumoral evaluation are warranted.
tudy limitations. Possible limitations of our study are the
elatively small sample size and the lack of autonomic tone
ssessment before and after the implantation of a CRT
evice. We assessed SDANN changes instead of standard
eviation of RR intervals (SDNN), the latter being more
requently used for evaluating autonomic nerve system
ctivity. However, SDANN and SDNN are closely related,
ave a high reproducibility, and have similar stability over
ime (25,26). The dynamic changes observed after implan-
ation may be related to implant procedure and consequent
educed physical activity during hospitalization. At the
resent time, the impact of bed rest, anesthesia, implanta-
ion procedure, and other factors on HR profile and HRV
s unknown. However, comparison of dynamic changes for
ach parameter between patients with a de novo implanta-
ion and those receiving a device replacement clearly showed
hat two weeks after implantation patients with device
eplacement reached a plateau that overlapped the values
eached three months after implantation by the patients
ith de novo implantation. Finally, the small number of
ardiovascular events occurring in patients with CRT did
ot allow us to further analyze the impact of HF exacerba-
ion and optimization of the device on the autonomicrofile. However, this issue has been investigated in great
etail in a larger number of patients and events by Adamson
t al. (7).
ONCLUSIONS
his study showed that CRT significantly modified the
ympathetic-parasympathetic influence to the heart, as as-
essed by HR profile and HRV. Significant changes of
RV time-domain parameters and HR profile were ob-
erved shortly after CRT and were sustained for years
hereafter. This positive effect on autonomic nervous system
odulation was consistent with improvement of functional
apacity and reverse remodeling. Suboptimal left ventricular
ead position was associated with no significant functional
nd structural improvement as well as no change or even
orsening of HRV. Lack of HRV improvement four weeks
fter CRT identified patients at higher risk for major
ardiovascular events, including death, urgent heart trans-
lantation, hospitalization for cardiovascular reasons, and
entricular arrhythmias. Thus, SDANN may be a useful,
bjective, and early parameter for identifying patients who
ay or may not respond to CRT and who may require
dditional interventions.
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PPENDIX
or the exponential fitting equation, please see the online
ersion of this article.
